Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Windtree Therapeutics, Inc. (WINT : OTC)

• Company Description    Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. The company's proprietary technology platform includes a synthetic, peptide-containing surfactant that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree Therapeutics, Inc., formerly known as Discovery Laboratories Inc., is based in Warrington, Pennsylvania. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $0.06 Daily Weekly Monthly 20 Day Moving Average: 4,118,902 shares Shares Outstanding: 29.33 (millions) Market Capitalization: $1.80 (millions) Beta: 0.57 52 Week High: $4.68 52 Week Low: $0.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -88.15% -88.36% 12 Week -88.87% -89.89% Year To Date -99.65% -99.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2600 KELLY ROAD SUITE 100 - WARRINGTON,PA 18976 USA ph: 215-488-9300 fax: 215-488-9301 ir@windtreetx.com https://windtreetx.com

• General Corporate Information    Officers Jed Latkin - Chief Executive Officer and President Mark Strobeck - Chairman Jamie McAndrew - Senior Vice President and Chief Financial Officer Craig E. Fraser - Director Leanne Kelly - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 97382D600 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/25/25 Share - Related Items Shares Outstanding: 29.33 Most Recent Split Date: 2.00 (0.02:1) Beta: 0.57 Market Capitalization: $1.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/25/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.16 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 99.71% vs. Previous Quarter: 33.91% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -207.34 03/31/25 - -227.93 12/31/24 - -195.91 ROA 06/30/25 - -50.19 03/31/25 - -56.46 12/31/24 - -55.73 Current Ratio 06/30/25 - 0.43 03/31/25 - 0.25 12/31/24 - 0.45 Quick Ratio 06/30/25 - 0.43 03/31/25 - 0.25 12/31/24 - 0.45 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 0.39 03/31/25 - 2.82 12/31/24 - 38.99 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©